openPR Logo
Press release

Dengue Pipeline Drugs, FDA Approvals, and Companies 2024

08-26-2024 03:11 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Dengue Pipeline

Dengue Pipeline

DelveInsight's, "Dengue- Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dengue Research. Learn more about our innovative pipeline today! @ Dengue Pipeline Outlook- https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Dengue Pipeline Report
• June 2024:- Janssen Research & Development LLC- A Phase 2, Randomized, Double-blind, Placebo-controlled, Double, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection. The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no evidence of current DENV infection at baseline.
• June 2024:- Novartis Pharmaceuticals- A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever. The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
• DelveInsight's Dengue pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Dengue treatment.
• The leading Dengue Companies such as Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
• Promising Dengue Therapies such as EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.

Stay informed about the cutting-edge advancements in Dengue Treatments. Download for updates and be a part of the revolution in infectious disease care @ Dengue Clinical Trials Assessment- https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dengue Emerging Drugs Profile
• VIS 513: Visterra
VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes found globally.

• TAK-003: Takeda
Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic "backbone" for all four vaccine viruses. Clinical Phase II data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.

• CDX DENV: Codagenix
Codagenix has leveraged the platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. CDX DENV, is a Synthetic vaccine being developed in the Pre-Clinical stage for the treatment of Dengue.

• AT 752: Atea Pharmaceuticals
AT-752, a diastomer of AT-527, is a novel purine nucleotide prodrug, designed to treat patients either newly infected or previously infected with the dengue virus. AT-752 has an favorable preclinical safety profile and has demonstrated potent in vitro activity against all dengue serotypes tested as well as potent antiviral activity in predictive animal models. Atea Pharmaceuticals plan to conduct clinical studies that will evaluate the daily administration of AT-752 over a short period of treatment, in order to negate the progression of infection and reduce the occurrence of life-threatening conditions associated with severe dengue.

Learn more about Dengue Drugs opportunities in our groundbreaking AL Dengue Research and development projects @ Dengue Unmet Needs- https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Dengue Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Dengue Treatment by visiting our website. Stay informed about how we're transforming the future of infectious disease @ Dengue Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dengue Pipeline Report
• Coverage- Global
• Dengue Companies- Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
• Dengue Therapies- EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.
• Dengue Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dengue Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dengue Pipeline on our website @ Dengue Drugs and Companies- https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Dengue: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dengue- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. TAK-003: Takeda
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AT 752: Atea Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dengue Key Companies
21. Dengue Key Products
22. Dengue- Unmet Needs
23. Dengue- Market Drivers and Barriers
24. Dengue- Future Perspectives and Conclusion
25. Dengue Analyst Views
26. Dengue Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
info@delveinsight.com
+91-9650213330

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dengue Pipeline Drugs, FDA Approvals, and Companies 2024 here

News-ID: 3635006 • Views:

More Releases from DelveInsight Business Research LLP

Brain Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034
Brain Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Ri …
The market size of Brain Cancer is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Genentech, Merck, Azurity Pharmaceuticals, Sevier, Kazia Therapeutics, Chimerix, Aivita Bio-medical, Medicenna Therapeutics [Nevada, United States] - DelveInsight's "Brain Cancer Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Brain Cancer, covering historical and predicted epidemiology, market trends,
Non-Small Cell Lung Cancer (NSCLC) Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight
Non-Small Cell Lung Cancer (NSCLC) Market to Witness Upsurge in Growth During th …
The market size of Non-Small Cell Lung Cancer (NSCLC) is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as novartis Pharmaceuticals, Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company Sanofi, Pfizer, Astellas Pharma/Seattle Genetics, Takeda Pharmaceuticals, Novartis, Merck/Pfizer, Mirati Therapeutics/Bristol-Myers Squibb/Beigene, Merck/GlaxoSmithKline, Amgen, Incyte Corporation. [Nevada, United States] - DelveInsight's "Non-Small Cell Lung Cancer (NSCLC)
Ascites Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034
Ascites Market Size is Set for Rapid Growth as Innovative Treatments and Rising …
The market size of Ascites is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Ocelot Bio, PharmaIN, Genfit, NovaShunt AG, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Protgen Ltd, Movetis, Sanofi, BioVie Inc., Versantis AG, Ocelot Bio, Inc, Mallinckrodt. [Nevada, United States] - DelveInsight's "Ascites Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed
Aplastic Anemia Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034
Aplastic Anemia Market Size is Set for Rapid Growth as Innovative Treatments and …
The market size of Aplastic Anemia is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Pfizer, BioLineRx Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals. [Nevada, United States] - DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Aplastic Anemia, covering historical and predicted

All 5 Releases


More Releases for Dengue

Dengue Vaccines Market 2021 | Detailed Report
Dengue Vaccines Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Dengue Vaccines Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4644240 The report provides a comprehensive analysis of company profiles listed below: - Sanofi - Takeda Dengue Vaccines Market Segment by
Dengue Fever - Pipeline Review, H1 2018
HTF Market Report released a new research document of 158 pages on industry titled as 'Dengue Fever - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as GeneSegues , GlaxoSmithKline , Globavir Biosciences , Immunotope etc The report will help you gain market insights, future trends and growth prospects for forecast period. Request a sample report @
Dengue Fever Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H1 2017, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape. Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It
Dengue Vaccines Market - Global Insights, 2016-2024
Dengue is a mosquito-borne flavivirus debilitating disease with high prevalence in most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the excruciating bone and joint pain associated with it. No therapeutics have been discovered for treatment of the disease caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4). Therefore, focus has been mainly on prevention by
Dengue Vaccine Market to be Driven by Rising Prevalence of Dengue and Increasing …
Dengue is a mosquito-borne infectious disease affecting humans and animals caused by dengue virus belonging to the Flaviviridae family and genus Flavivirus. Dengue is typically transmitted from human to human through the bite of an infected aedes aegypti mosquito. Symptoms of dengue include high fever, headache, fatigue, muscle pain, diarrhea, anemia, skin rashes and vomiting. Severe dengue can cause yellow skin, seizures, coma, or death. Dengue has high mortality rate
Dengue Vaccine Market to be Driven by Rising Prevalence of Dengue and Increasing …
Dengue is a mosquito-borne infectious disease affecting humans and animals caused by dengue virus belonging to the Flaviviridae family and genus Flavivirus. Dengue is typically transmitted from human to human through the bite of an infected aedes aegypti mosquito. Symptoms of dengue include high fever, headache, fatigue, muscle pain, diarrhea, anemia, skin rashes and vomiting. Severe dengue can cause yellow skin, seizures, coma, or death. Dengue has high mortality rate